The airway epithelium of smokers acquires pathological phenotypes, including basal cell (BC) and/or goblet cell hyperplasia, squamous metaplasia, structural and functional abnormalities of ciliated cells, decreased number of secretoglobin (SCGB1A1)-expressing secretory cells, and a disordered junctional barrier. In this study, we hypothesized that smoking alters airway epithelial structure through modification of BC function via an EGF receptor (EGFR)-mediated mechanism. Analysis of the airway epithelium revealed that EGFR is enriched in airway BCs, whereas its ligand EGF is induced by smoking in ciliated cells. Exposure of BCs to EGF shifted the BC differentiation program toward the squamous and epithelial-mesenchymal transition-like phenotypes with down-regulation of genes related to ciliogenesis, secretory differentiation, and markedly reduced junctional barrier integrity, mimicking the abnormalities present in the airways of smokers in vivo. These data suggest that activation of EGFR in airway BCs by smoking-induced EGF represents a unique mechanism whereby smoking can alter airway epithelial differentiation and barrier function.
The airway epithelium of smokers acquires pathological phenotypes, including basal cell (BC) and/or goblet cell hyperplasia, squamous metaplasia, structural and functional abnormalities of ciliated cells, decreased number of secretoglobin (SCGB1A1)-expressing secretory cells, and a disordered junctional barrier. In this study, we hypothesized that smoking alters airway epithelial structure through modification of BC function via an EGF receptor (EGFR)-mediated mechanism. Analysis of the airway epithelium revealed that EGFR is enriched in airway BCs, whereas its ligand EGF is induced by smoking in ciliated cells. Exposure of BCs to EGF shifted the BC differentiation program toward the squamous and epithelial-mesenchymal transition-like phenotypes with down-regulation of genes related to ciliogenesis, secretory differentiation, and markedly reduced junctional barrier integrity, mimicking the abnormalities present in the airways of smokers in vivo. These data suggest that activation of EGFR in airway BCs by smoking-induced EGF represents a unique mechanism whereby smoking can alter airway epithelial differentiation and barrier function. (1, 2) . BCs are the stem/progenitor cells for the airway epithelium. Normal BC function includes generation of airway basal, secretory, and ciliated cells (3) (4) (5) . Cigarette smoking is associated with dramatic changes in the airway epithelial architecture, inducing BC hyperplasia, mucus overproduction, and squamous metaplasia (6, 7) . Squamous metaplasia represents a histological lesion characterized by conversion to a stratified epithelium comprised of flattened squamous cells replacing the differentiated cell populations (6, 7) . Other smoking-induced changes include structural and functional abnormalities of ciliated cells (8, 9) , disorganization of cell-cell junctions leading to increased permeability of the airway epithelial barrier (10) (11) (12) , and decreased numbers of secretoglobin (SCGB) 1A1-expressing secretory cells (13) . Persistence of these changes in the context of chronic cigarette smoking is associated with decreased mucociliary clearance, pathogen colonization, and development of smokingassociated lung disorders, chronic obstructive pulmonary disease, and lung cancer (6, 7, (14) (15) (16) .
Altered BC function might be one possible mechanism of smoking-induced dysregulation of airway epithelial differentiation. Consistent with this concept are the observations of increased numbers of BCs in the airways of smokers (6, 7) , overexpression of BC markers keratin (KRT) 5, KRT14, and tumor protein (TP) 63 in squamous lesions (6, 17) , and the ability of BCs to form squamous epithelium in vitro (18) . A molecular mechanism contributing to smoking-induced changes in BC function could be activation of EGF receptor (EGFR), a member of the ErbB (v-erb-b oncogene homolog) family of tyrosine kinase receptors (19) . EGFR is enriched in cells of the basal layer of various epithelial tissues, including the airways (20) (21) (22) , and has been implicated in regulation of epithelial homeostasis and tissue repair, production of host defense mediators, and production of mucin (23) (24) (25) . Increased EGFR tyrosine phosphorylation, indicative of EGFR receptor activation, has been observed in airway epithelial cells exposed to cigarette smoke in vitro (26, 27) .
Based on this knowledge, we hypothesized that smokinginduced changes in the EGFR pathway are relevant to the EGFRdependent modification of BCs toward the abnormal differentiation phenotypes present in the airway epithelium of smokers. In this study, we provide evidence that although EGFR is expressed predominantly in BCs, smoking induces expression of EGF in ciliated cells of the airway epithelium, and activation of airway BCs with EGF skews their differentiation from the normal mucociliary pathway toward the squamous and epithelialmesenchymal transition (EMT)-like phenotypes with decreased epithelial junctional barrier integrity.
Results
Enrichment of EGFR Gene Expression in Airway Basal Cells. Signaling through various ErbB family receptors in polarized epithelia, including that in the airways, is determined, at least in part, by segregated distribution of the receptors and their ligands in either apical or basolateral membrane domains (28, 29) . We hypothesized that an additional compartmentalization could be provided by the heterogeneous expression of the ErbB family receptors and their ligands between the BC and BC-derived differentiated cell populations, such as ciliated and secretory cells, contributing to the luminal compartment. Microarray-based gene expression analysis of the complete large airway epithelium (LAE) compared with the LAE-derived BCs from healthy nonsmokers revealed compartmentalized expression of the EGFR family receptors in the normal human airway epithelium in vivo (Fig. 1A) .
Consistent with previous immunohistochemistry findings (20, 22, 29) , EGFR gene expression was much greater compared with other ErbB receptors and was enriched in BCs (Fig. 1A) . In contrast, expression of ERBB4 was barely detectable in BCs, but was significantly greater in differentiated airway epithelium (Fig.  1A ). These differences were related to cell differentiation status and not to the culture itself, given that expression of neither EGFR nor ERBB4 varied significantly during the expansion phase, when BCs were grown as submerged cultures (Fig. S1 A  and B) . However, EGFR gene expression was dramatically decreased and ERBB4 expression was markedly increased during the BC differentiation phase in the air-liquid interface (ALI) model, recapitulating the expression pattern observed in the airway epithelium in vivo (Fig. S1 A-C) .
Enrichment of EGFR expression in the BC population was further confirmed through immunohistochemistry analysis of LAE biopsy specimens and freshly isolated LAE brushed cells (Fig. 1B) . Immunofluorescence analysis of the airway epithelial brushings obtained from different donors (Fig. 1B and Fig. S2A ) revealed that >80% of EGFR-expressing cells were positive for BC marker keratin KRT5, and that >70% of BCs expressed EGFR (Fig. S2B) . The latter finding points toward heterogeneity of BCs in terms of EGFR protein expression. This heterogeneous pattern of EGFR expression was preserved in BCs cultured from freshly isolated airway epithelium ( Fig. 1C and Fig.  S2C ). EGFR protein level decreased progressively when BCs generated differentiated airway epithelium in the ALI culture (Fig. 1D) , where EGFR expression was restricted to a subset of KRT5-expressing cells, that is, BCs (Fig. 1E ).
Smoking-Induced EGF Expression in Ciliated Cells of the Airway Epithelium. To assess whether cigarette smoking is associated with abnormal expression of the EGFR family receptors and ligands in the airway epithelium, we compared expression of these genes in the LAE of healthy smokers and healthy nonsmokers. The data demonstrate that in the LAE of smokers, expression of genes encoding EGFR, ErbB2, and TGF-α (an EGFR ligand) was down-regulated (Fig. S3A) . In contrast, expression of EGF, a major EGFR ligand usually expressed in the surface airway epithelium at relatively low levels (20, 29) , was significantly up-regulated in the complete LAE of smokers, but not in the BCs (Fig. 2A) . Genome-wide correlation analysis revealed strong coexpression of EGF with the genes related to the nuclear factor (erythroid-derived 2)-like 2 (Nrf2)-dependent oxidative stress response (Fig. S3B) . EGF up-regulation in the airway epithelium of smokers was further confirmed by RNA-sequencing (RNA-Seq) analysis (Fig. 2B) . Consistent with this observation, immunohistochemistry analysis revealed increased EGF protein expression in the airway epithelium of smokers ( Fig. 2C and Fig.  S3C ) with selective enrichment in ciliated cells, the major differentiated cell population of the airway epithelium (1), which composed the majority (84.5 ± 15.6%) of EGF-expressing cells in the airway epithelium of smokers (Fig. 2D ).
To determine whether cigarette smoke can directly induce EGF in the differentiated airway epithelium, we applied cigarette smoke extract (CSE) to the differentiated airway epithelium generated from BCs in ALI culture. For modeling of repeated prolonged smoking exposure, CSE was added from the apical side for 24 h every other day over a 2-wk period. Significant up-regulation of EGF gene expression was observed in differentiated airway epithelial cells stimulated with CSE (Fig.  2E ). The levels of EGF protein released from the apical surface were significantly higher than those detected in the basolateral compartment of the ALI culture (Fig. 2F ). Given that ciliated cells are the predominant cell population contributing to the apical compartment of the ALI-differentiated airway epithelium (4, 30) , this observation is in agreement with the in vivo data showing that ciliated cells are the major source of EGF in the airway epithelium of smokers.
EGF Alters Basal Cell Phenotype and Differentiation. To evaluate whether EGF is capable of activating EGFR in airway BCs, we performed Western blot analysis and receptor tyrosine kinase (RTK) protein array analysis, which confirmed that EGF induces phosphorylation of EGFR (Fig. 3A) , but not of other receptor tyrosine kinases (Fig. S4 ), in BCs. EGF altered the appearance of airway BCs from their normal cuboidal shape toward an elongated morphology with apparent loss of intercellular contacts ( Fig. 3B and Fig. S5A ). Such morphology, typical of motile epithelial cells undergoing EMT (31) , was observed in >30% of EGF-treated BCs, compared with <1% in the control group (Fig. S5B) .
To study the effect of EGF on the airway BC differentiation, we took advantage of the ALI model, in which BCs generate a fully differentiated polarized airway epithelium (4, 21, 32) . Our analysis, performed in the middle (day 14) of the differentiation process, revealed that EGF broadly modifies the BC differentiation program by inducing expression of KRT6, KRT14, involucrin (IVL), and stratifin (SFN), all of which are related to various aspects of epithelial injury and squamous differentiation (16, 17) , as well as CD44, a gene often associated with epithelial stem cell phenotype (33) (Fig. 3C ). This was accompanied by upregulation of genes indicative of EMT, including the epithelial transcriptional repressor snail homolog 2 (SNAI2, also known as SLUG), and the mesenchymal marker vimentin (VIM) (Fig. 3C) . In contrast, EGF down-regulated the physiological BC marker KRT5 and genes relevant to specialized differentiated airway epithelial cell populations, such as the ciliated cell-related genes forkhead box J1 (FOXJ1) and dynein, axonemal, intermediate chain 1 (DNAI1) and the secretory cell-related markers mucin (MUC) 5B and SCGB1A1 (Fig. 3C) . The effect of EGF on the expression of many of these genes was detectable starting during the first week of ALI and remained significant throughout the differentiation process (Fig. S6) . In contrast to basolateral stimulation, which allows activation of EGFR expressed on BCs, apical application of EGF did not induce similar gene expression changes in differentiation-related pathways (Fig. S7A) .
Consistent with the gene expression data, immunofluorescence analysis and morphological evaluation of cytopreparations and sections of the airway epithelium generated over 28 d in ALI culture demonstrated that EGF treatment of BCs resulted in a remarkable increase in the number of cells expressing squamous cell markers KRT14 and IVL and the EMT marker VIM (Fig. 3 D and E and Figs. S8 and S9 A and B). In the airway epithelium derived from EGF-treated BCs, >20% of cells expressed IVL or VIM, compared with <5% in the control group (Fig. 3F) . The vast majority of cells expressing IVL or VIM in the EGF-treated group (>95% and >90%, respectively) were KRT5 + (Fig. S10) , suggesting that BCs undergo differentiation toward the squamous and EMT-like phenotypes in response to EGF. This was accompanied by a decreased proportion of KRT5 − (i.e., nonbasal) cells in the EGF-treated group (Fig. 3F ), pointing toward a reduction in the differentiated cell frequency. Although the overall absolute numbers of ciliated and secretory cells were not statistically different between the groups (data not shown), the airway epithelium generated from the EGF-treated BCs contained multiple areas characterized by loss of ciliated and SCGB1A1-secreting cells (Fig. S9 C and D) . analysis of EGF-treated BCs during their differentiation in ALI revealed significant down-regulation of genes relevant to the establishment of epithelial polarity and apical junction formation, including cadherin 1 (or E-cadherin) (CDH1), tight junction protein (TJP) 1 and 3, claudin (CLDN) 3 and 8, occludin (OCLN), epithelial polarity complexes par-3 partitioning defective homolog (PARD3) and par-6 partitioning defective homolog (PARD6B), and tumor suppressor phosphatase and tensin homolog (PTEN) (Fig. 4A) . Of note, all of these genes were found to be down-regulated in our previous study of gene expression in the airway epithelium of smokers in vivo (12) . Consistent with the gene expression data, EGF-treated BCs generated airway epithelia with markedly reduced transepithelial electrical resistance (Rt), a measure of epithelial junctional barrier integrity (34), compared with the control group (Fig. 4B) . The addition of EGF to differentiated cells (i.e., from the apical side) did not result in either suppression of the epithelial junction/ polarity genes or reduced Rt compared with unstimulated control cells (Fig. S7B) . The negative effect of EGF application to BCs on Rt during airway epithelial differentiation was prevented when the EGFR-selective tyrosine kinase inhibitor AG1478 was added to the basolateral compartment before the EGF treatment (Fig.  4C) . Finally, significantly increased paracellular flux of the apically added dextran to the basolateral media was observed in the airway epithelium derived in ALI from the EGF-treated BCs, indicative of decreased barrier function (Fig. 4D ).
Discussion
The airway epithelium of smokers is disordered with BC hyperplasia, squamous metaplasia, goblet cell hyperplasia/metaplasia and mucus overproduction, altered structure and function of ciliated cells, decreased numbers of SCGB1A1-expressing secretory cells, and dysregulation of the apical junctional complex (AJC) controlling epithelial permeability (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . Our data demonstrate that EGF is produced by ciliated cells in response to smoking and modifies the differentiation capacity of EGFRexpressing airway BCs, leading to the development of altered differentiation phenotypes similar to those present in the airway epithelium of smokers (Fig. S11) .
EGF-EGFR Segregation in the Airway Epithelium and Smoking.
A major feature of the differentiated airway epithelium is its polarized organization, that is, compartmentalized distribution of distinct membrane-associated signaling domains along the apical and basolateral surfaces separated by tight and adherens junctions between adjacent epithelial cells (34) . This mechanism provides separation of receptors from their ligands usually positioned at the opposite membrane poles, preventing aberrant receptor activation under steady-state conditions but allowing receptor activation in response to injury when the junctional barrier is disrupted (29) , as occurs in the airway epithelium of cigarette smokers (10) (11) (12) . Originally observed in Madin-Darby canine kidney (MDCK) cells (28), polarized distribution of the EGFR and its ligands along the basal-apical axis of the epithelial cell membrane has been reported in airway epithelial cells as well (20, 29, 35) .
Our findings in the present study extend this concept by demonstrating an additional level of EGF-EGFR compartmentalization in the human airway epithelium that is sensitive to the smoking-induced injury. Our analysis revealed that EGFR is normally enriched in BCs, a population of cells located immediately above the basement membrane and containing stem/ progenitor cells of the airway epithelium (3-5), whereas its ligand EGF is expressed in the surface airway epithelium at barely detectable levels but is significantly induced by smoking in ciliated cells, a cell population contributing to the differentiated luminal compartment of the airway epithelium (1).
Cigarette smoking-induced oxidative stress has recently been linked to EGFR activation in human lung epithelial cells in vitro (36) (37) (38) . Consistent with this concept, the present study revealed a strong correlation between EGF expression and the genes related to the Nrf2-dependent oxidative stress response in the airway epithelium of smokers previously reported by our group (39) . Thus, in conjunction with previous observations of compromised junctional barrier integrity in the airway epithelium of smokers (10) (11) (12) , our present data suggest that smoking can activate physiologically silenced EGF-EGFR signaling in the airway epithelium by inducing EGF production by ciliated cells as part of the oxidative stress response and potentially allowing access of EGF to the EGFR-enriched BC compartment containing stem/progenitor cells of the airway epithelium. Our analysis revealed that not all BCs express EGFR to the same degree, suggesting that distinct subpopulations of airway BCs may exist, each with a unique sensitivity to smoking-associated tissue damage and a unique contribution to smoking-induced disordering of the airway epithelial phenotype. and epithelial polarity: CDH1, TJP1,  TJP3, CLDN3, CLDN8 , OCLN, PARD3, PARD6B, and PTEN. The data were generated during 14 d of ALI culture of BCs stimulated with 10 ng/mL EGF (n = 4) vs. unstimulated controls (n = 4). (B) Rt of the airway epithelium generated from BCs stimulated with EGF (10 ng/mL) vs. unstimulated control cells at different time points of the ALI culture. (C) Rt of the airway epithelium generated at day 14 of ALI culture from BCs treated with media only (control), DMSO (vehicle for AG1478), EGFR inhibitor AG1478 (10 μm), and EGF (10 ng/mL) with or without a 1-h pretreatment with AG1478 (10 μm) every second day starting on day 0 of ALI. (D) Mean fluorescence intensity detected in the basolateral chamber of ALI at different time points after apical application of FITC-dextran to the airway epithelium samples differentiated in ALI from EGF-treated or control BCs. In B-D, asterisks indicate statistically significant differences at given time points between EGF-stimulated and control groups: *P < 0.05; **P < 0.01; ***P < 0.005.
Similar to other smoking-associated molecular changes in the airway epithelium (12, 39) , EGF expression varied considerably, demonstrating marked up-regulation in a subset of smokers. Given that smoking-induced pathological changes in the airway epithelium, including squamous metaplasia (7), and smokingassociated diseases, such as chronic obstructive pulmonary disease and lung cancer, develop in <25% of smokers (40, 41) , and considering the capability of EGF to alter airway epithelial phenotype demonstrated in the present study, it is possible that increased expression of EGF in the airway epithelium defines a distinct subset of smokers susceptible to the development of smoking-related airway pathology.
EGF-Modified BCs as a Cellular Origin of Squamous Metaplasia. Airway BCs are stem/progenitor cells that normally can differentiate into ciliated and secretory cells (3) (4) (5) . Using an ALI model of BC differentiation (4, 21, 30, 32) , we found that exposure of BCs to EGF during their differentiation in this culture system significantly decreases the ability of BCs to generate normal mucociliary airway epithelium and skews differentiation toward the squamous phenotype, characterized by up-regulation of various genes associated with squamous differentiation and increased numbers of cells expressing squamous cell markers. Among these genes are IVL and KRT14, which have low expression in the normal surface airway epithelium but are markedly up-regulated in BCs undergoing squamous differentiation (16, 17) . Of note, >95% of squamous cells in the airway epithelium generated from the EGF-treated BCs coexpressed BC marker KRT5, suggesting that these cells are the result of directly EGF-mediated BC differentiation toward the squamous phenotype. In further support of the BC origin of EGF-induced squamous metaplasia, upregulation of the squamous differentiation program in response to basolateral EGF stimulation was detected at day 14 of ALI, when few differentiated cells are normally present (21, 30) .
Consistent with this idea are the findings that squamous metaplasia commonly develops as a consequence of smoking-induced BC hyperplasia (6, 7), airway BCs can give rise to squamous airway epithelium in vitro (18) , and expression of EGF and the number of EGFR-expressing cells are increased within squamous lesions in an in vivo model of airway injury (42) . Given that squamous metaplasia is one of the early major smoking-induced lesions in the airway epithelium linked to smoking-induced carcinogenesis (6, 7) , and that EGFR is commonly overexpressed and activated in squamous cell lung carcinomas, a subtype of nonsmall cell lung carcinoma (NSCLC) associated with smoking (43), it is possible that EGF-activated BCs contribute to the development of the early premalignant squamous lesions in the airway epithelium of smokers. Consistent with this concept, cells expressing KRT14, a squamous-associated gene induced by EGF in airway BCs in our study, are enriched in the non-small cell lung carcinoma tissue in association with smoking status (17) .
In the present study, similar to squamous metaplasia in the airways of smokers, characterized by the progressive disappearance of normal differentiated cells contributing to the luminal epithelial compartment (7), the squamous phenotype in the airway epithelium generated in vitro from EGF-treated BCs was accompanied by broad suppression of the genes associated with ciliated and secretory cell differentiation, including transcription factor FOXJ1, which is critical for ciliogenesis (44) ; structural cilia gene DNAI1 (45) ; nonmucous secretory cell-associated gene SCGB1A1 (2); and serous secretory cell gene MUC5B (46) . Consistent with these observations, the presence of EGF during the differentiation of rat tracheal epithelial cells in vitro has been shown to be inversely correlated with the number of ciliated cells generated (32) .
EGF-Modified BCs and EMT. EGF-mediated differentiation of BCs toward the squamous phenotype was accompanied by molecular changes associated with the EMT, a process characterized by the loss of some of differentiated epithelial features and acquisition of the mesenchymal-like phenotype (31) . Several key characteristics of the EMT were induced by EGF in airway BCs, including acquisition of the elongated shape, up-regulation of the key EMTinducing transcription factor SNAI2/SLUG, and induction of VIM, an intermediate filament characteristic of mesenchymal cells and migrating epithelial cells (31, 47) . Up-regulation of VIM was observed after basolateral stimulation of BCs with EGF as early as within 3 d of BC differentiation in ALI, long before the appearance of differentiated cells, and was not induced in differentiated airway epithelium after apical application of EGF, suggesting that BCs undergo EGF-mediated EMT-like changes.
In further support of the BC origin of EGF-induced EMT-like phenotype, VIM-expressing cells, which appeared in the airway epithelium derived from EGF-treated BCs, were found to coexpress BC marker KRT5. This finding argues against transition toward a mesenchymal cell type and supports the concept that EGF shifts BCs toward an EMT-like, rather than a classical EMT, phenotype. Parallel acquisition of squamous and EMTlike phenotypes by EGF-treated BCs points toward the common BC origin, coordinated EGFR-mediated mechanism, and potentially integrated roles of these two processes in the suppression of normal airway epithelial differentiation.
Acquisition of the EMT-like phenotype was accompanied by a broad down-regulation of the genes encoding various AJC components, including epithelial-specific CDH1, tight junction genes, PARD-family polarity complexes, and tumor suppressor PTEN, critical for epithelial morphogenesis (48) , recently shown to be a part of the smoking-sensitive AJC transcriptional network in the airway epithelium (12) . Consistent with this, airway epithelium generated from the EGF-treated BCs exhibited decreased barrier integrity, manifested by significantly reduced Rt and increased paracellular permeability. A similar pattern of AJC-related features is down-regulated in the airway epithelium of smokers in vivo (12) , suggesting that smoking-associated alteration of the airway epithelial barrier integrity may be related, at least in part, to the EMT-like phenotype induced by EGF in airway BCs.
EGF-induced impairment of the airway epithelial junctional barrier provides a mechanism whereby ciliated cell-derived EGF may access EGFR-expressing BCs and sustain EGFR-mediated modification of airway epithelial differentiation. This persistent BC activation via the EGF-EGFR pathway may be responsible for the progressive alteration of airway architecture and subsequent development of preneoplastic lesions. Consistent with this concept, EMT-like changes have been linked to acquisition of the stem cell/tumor-initiating phenotype (33) , and EGF has been shown to induce EMT in carcinoma cells (49, 50) . In addition, persistent EGFR activation and acquisition of the EMT phenotype may eventually lead to the development of resistance to EGFR tyrosine kinase inhibitors (26, 51) .
In summary, our findings demonstrate that EGFR expression is enriched in airway BCs, whereas its ligand EGF is induced by smoking in ciliated cells of the airway epithelium. EGF skews the airway BC fate toward abnormal, squamous and EMT-like phenotypes with marked suppression of the normal differentiation features, similar to the morphological changes seen in the airway epithelia of smokers in vivo. Selective targeting of the EGF-EGFR pathway in airway BCs may be a useful strategy for preventing the development of smoking-induced lung disorders, including lung cancer, at early stages.
Methods
Airway Epithelium and BCs. LAE from healthy nonsmokers (n = 21) and healthy smokers (n = 31) was collected by bronchoscopic brushing of the third-to fourth-order bronchi as described previously (12) . Subjects were recruited under a protocol approved by the Weill Cornell Medical College Institutional Review Board, with written informed consent obtained from each volunteer before enrollment in the study. Cells were processed and BCs isolated as described previously (12) .
Gene Expression Analysis. Total RNA was extracted, and double-stranded cDNA and microarray analyses were performed using HG-U133 Plus 2.0 microarrays as described previously (12) . In in vitro experiments, expression of selected genes was analyzed by TaqMan real-time RT-PCR using specific TaqMan gene expression assays (Applied Biosystems) (12) . RNA-Seq analysis of the airway epithelium samples was performed as described previously (52) .
In Vitro Studies. The capacity of BCs to generate differentiated airway epithelium in the presence or absence of EGF (10 ng/mL; Sigma-Aldrich) was assessed using the ALI model (21) . The CSE stimulations were carried out as described in SI Methods. Levels of EGF released after CSE stimulation were determined using a commercially available DuoSet ELISA Development Kit for EGF (R&D Systems) according to the manufacturer's instructions. The effect of EGF on BC morphology and EGFR activation was assessed as described in SI Methods. Epithelial barrier integrity was assessed by measuring Rt and paracellular permeability using an FITC-dextran flux assay, as described in SI Methods.
Analysis of Protein Expression. Western blot analysis of the total and phosphorylated EGFR protein was performed as described in SI Methods. Human phospho-RTK antibody Proteome Profiler Array (R&D Systems) analysis was performed according to the manufacturer's protocol. Immunohistochemistry and immunofluorescence analyses were performed using previously reported protocols (12, 21) , as described in SI Methods.
